Novel oral transforming growth factor‐β signaling inhibitor EW‐7197 eradicates CML‐initiating cells

Recent strategies for treating CML patients have focused on investigating new combinations of tyrosine kinase inhibitors (TKIs) as well as identifying novel translational research agents that can eradicate CML leukemia‐initiating cells (CML‐LICs). However, little is known about the therapeutic benef...

Descripción completa

Detalles Bibliográficos
Autores principales: Naka, Kazuhito, Ishihara, Kaori, Jomen, Yoshie, Jin, Cheng Hua, Kim, Dong‐Hyun, Gu, Yoon‐Kang, Jeong, Eun‐Sook, Li, Shaoguang, Krause, Daniela S., Kim, Dong‐Wook, Bae, Eunjin, Takihara, Yoshihiro, Hirao, Atsushi, Oshima, Hiroko, Oshima, Masanobu, Ooshima, Akira, Sheen, Yhun Yhong, Kim, Seong‐Jin, Kim, Dae‐Kee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4768399/
https://www.ncbi.nlm.nih.gov/pubmed/26583567
http://dx.doi.org/10.1111/cas.12849

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4768399/
https://www.ncbi.nlm.nih.gov/pubmed/26583567
http://dx.doi.org/10.1111/cas.12849

Ejemplares similares